ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

ELCC 2025| Professor Wei Zhang on the Optimal Duration of Immunotherapy and Novel Strategies Beyond PD-(L)1 Inhibition

2025.04.20
The recently concluded 2025 European Lung Cancer Congress (ELCC) spotlighted several key clinical topics and unveiled new research with strong translational potential. Oncology Frontier invited Professor Wei Zhang of Shanghai Chest Hospital, Shanghai Jiao Tong University for an in-depth interview, where she shared expert insights on the congress's most impactful themes and dissected the scientific highlights shaping the future of lung cancer treatment.
ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China

ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China

2025.04.17
A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to existing standards, while maintaining a favorable safety profile. Most notably, this strategy set a new survival benchmark for first-line immunotherapy in SCLC, demonstrating the value of integrating immune checkpoint inhibition with thoracic radiotherapy. This innovative approach represents a major step forward in SCLC treatment and offers renewed hope for patients battling this aggressive disease. In light of these findings, Oncology Frontier invited Academician Jinming Yu to share insights into the study design, key outcomes, and its clinical implications. The following is a summary of his expert commentary.
CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

2025.04.17
At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s scientific innovation capacity in oncology. Following the session, Oncology Frontier invited Academician Yu to share his perspectives on the clinical application of radiotherapy in breast cancer, strategies for advancing China's global competitiveness in oncology, and his long-standing commitment to cultivating young academic talent.
Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

Professor Michael Gnant, SGBCC President, Visits The Second Hospital of Dalian Medical University for Academic Exchange on Cutting-Edge Breast Cancer Diagnosis and Treatment

2025.04.15
The St. Gallen International Breast Cancer Conference (SGBCC) is one of the most authoritative and influential global events in the field of breast cancer, dedicated to advancing standardized diagnosis and treatment for early-stage breast cancer. To integrate international frontier concepts with domestic clinical practice and align China’s breast cancer care with global standards—ultimately delivering superior treatment options for patients—Professor Michael Gnant, President of SGBCC, visited The Second Hospital of Dalian Medical University on April 9 for a two-day academic exchange and collaboration initiative.